Analyst Eyes Over 2,277% in Upside Potential with a $3.50 Target as This Low-Float BioPharma Comes Off its 52-Week Low… (27)(1)

See why now could be the best time to start your research on NovaBay Pharmaceuticals, Inc. (AMEX: NBY)

5 Reasons Why NovaBay Pharmaceuticals, Inc. (AMEX: NBY) Could Be Poised For Significant Upside Potential as we Move into 2024!

1. Positive Analyst Outlook: Director of Research and Senior Analyst for Ascendiant Capital Markets, LLC, Edward Woo, has recently conveyed optimistic views and offered favorable perspectives on NovaBay Pharmaceuticals, Inc. (AMEX: NBY) with a $3.50 target, , which suggests over 2,277% in potential upside from its 52-week low. (27)  

2. Strong Q3 Results: Recently, NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) unveiled its financial results for the third quarter of 2023, and the figures reveal an encouraging and promising narrative for the company. This announcement provides valuable insights into NovaBay’s performance and strategic direction, shedding light on their achievements and plans for the future.

3. QVC Collaboration: NovaBay’s collaboration with QVC represents a strategic move towards expanding its market reach. QVC is a widely recognized and trusted shopping network that reaches millions of viewers, providing a platform for NovaBay to showcase its dermatology products to a diverse and extensive audience. (33)

4. Robust Product Portfolio: NovaBay Pharmaceuticals, Inc. (AMEX: NBY) boasts a robust product portfolio, including its Avenova-branded eye care products, DERMAdoctor skin care products, and PhaseOne wound care products. This diverse range of offerings positions the company well within the healthcare industry and presents multiple avenues for growth. (19)

5. Promising Future: NovaBay Pharmaceuticals, Inc. (AMEX: NBY)’s recent achievements, including the shipment of a significant order for NeutroPhase Skin and Wound Cleanser, highlight their potential for future success. The company’s ongoing initiatives and strategic partnerships indicate a commitment to capitalizing on market opportunities and delivering long-term value. (20)

Market Insights Indicate Significant Growth Potential with a Combined Valuation of Over $783 Billion…(16)(17)(18)

Image Source (16)

The global markets for ophthalmic therapeutics, psoriasis treatment, and cosmetics are experiencing rapid growth and offer lucrative opportunities. The ophthalmic therapeutics market, valued at $37.35 billion in 2022, is projected to reach approximately $65.53 billion by 2032. (16) 

This market focuses on the development of therapeutics and formulations for treating various eye conditions such as glaucoma, cataracts, and macular degeneration. The growing investments in research and development activities, along with the increasing aging population, are driving market growth. (16)

Similarly, the global psoriasis treatment market, valued at $27.10 billion in 2022, is estimated to reach around $57.70 billion by 2032. Psoriasis is an autoimmune inflammatory skin disorder characterized by symptoms like dryness, itching, bleeding, and local irritation. (17)

The market offers various treatments for different types of psoriasis, including psoriatic arthritis and plaque psoriasis. The increasing prevalence of psoriasis, particularly among the geriatric population, has led to a surge in demand for effective treatment options. (17)

Image Source (18)

The cosmetics market, valued around $378 billion in 2022, is poised to reach approximately $661 billion by 2032. Factors such as shifting lifestyles, rising per capita income, urbanization, and the expanding middle-class consumer base drive this growth. (19) 

The market has witnessed a rising demand for natural cosmetics products, fueled by consumer preferences for herbal and natural ingredients. (18)

Cosmetic skincare products are estimated to reach $185 billion by 2027. The skincare segment is growing faster than any other part of the beauty industry. (19)

Amidst these flourishing markets, NovaBay Pharmaceuticals, Inc. (AMEX: NBY) emerges as one company to keep a close eye on.

NovaBay Pharmaceuticals, Inc. (AMEX: NBY): Analyst Places $3.50 Target Which Suggests Remarkable Upside Potential of Over 2,277% (1)(27)

Chart Source (32)

Edward Woo, an analyst at Ascendiant Capital Markets LLC, has recently drawn attention by placing a $3.50 target on shares of NovaBay Pharmaceuticals, Inc. (AMEX: NBY). This target suggests a jaw-dropping upside potential of over 2,277% from NBY’s 52-week low of $.1472, set on 1/8/2024, according to Barchart.com, making NovaBay an intriguing research prospect. Let’s delve into the details of the recent developments and the analyst’s rationale behind this bold target. (27) 

Q3 Report and Financial Performance
NovaBay Pharmaceuticals recently reported its third-quarter results for 2023, which shed light on its financial performance. Despite revenue coming in at $3.3 million, reflecting a 15% year-over-year decline, the results still exceeded expectations. Analysts had estimated revenue at $3.8 million, and consensus estimates were slightly lower at $3.6 million. In terms of net loss, NovaBay reported $1.8 million, translating to an EPS of $(0.37), which also outperformed expectations. Analysts had predicted a loss of $(0.41), while consensus estimates stood at $(0.40). (27)

One notable aspect of NovaBay’s performance is that it did not provide specific guidance for 2023, leaving room for potential upside surprises in the coming quarters. (27)

Avenova Products Sales and DERMAdoctor Contribution
A significant part of NovaBay’s revenue came from Avenova product sales, totaling $2.4 million. Additionally, the company generated $0.1 million from NeutroPhase and PhaseOne wound care product sales. DERMAdoctor, acquired by NovaBay for approximately $12 million in cash in September 2021, contributed $0.8 million in sales during the quarter. DERMAdoctor offers a range of skincare products designed to address various skin conditions and is sold through major retailers such as Macy’s, QVC, and Amazon. (27)

Shift in DERMAdoctor Strategy
NovaBay Pharmaceuticals is making strategic shifts within its skincare segment. The focus is now on driving sales of top-selling products through efficient sales channels, moving away from new product development. As part of this shift, the founders of DERMAdoctor, Dr. Jeff Kunin and Dr. Audrey Kunin, retired in November 2023. (27)

Long-Term Positive Outlook
Despite the ups and downs in stock and financial results, Edward Woo remains positive about NovaBay’s potential. The company’s primary focus for 2023/24 is to expand the market reach of Avenova and DERMAdoctor products, both current and upcoming. NovaBay aims to tap into the substantial market opportunity represented by the 41 million Americans suffering from blepharitis and related eye symptoms, with a $600 million market potential. (27)

Balance Sheet and Risk/Reward Analysis
NovaBay Pharmaceuticals maintains a reasonably healthy balance sheet, with $4 million in cash and $1 million in debt during the third quarter. In the second quarter, the company secured $3 million in convertible debt financing. This financial position suggests that NovaBay has sufficient cash to sustain its operations into 2024. (27)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) is showing signs of promise and resilience in the healthcare industry, particularly in the eyecare and skincare segments. With an analyst projecting substantial upside potential, industry stakeholders should be closely watching NovaBay’s journey as it navigates the dynamic healthcare market and seeks to capitalize on its existing products and strategic acquisitions. (27)

Warning: Do Not Ignore the Low Float of NovaBay Pharmaceuticals, Inc. (AMEX: NBY)

Image Source (8)

Low float stocks refer to the securities that remain after a company’s stock has been issued to its controlling investors — meaning there are relatively few shares for the public to buy. (3) 

Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions.

Companies with a low float frequently have a large portion of their equity held by controlling investors such as directors and employees, which leaves only a tiny percentage of the stock available for public trading.

Because low-float stocks have fewer shares available, market participants may have difficulty finding shares available.

That limited supply can cause dramatic swings if demand changes quickly. (3)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has just under 6.54 million shares in its float as of 1/8/2024, according to Finviz.com. (2)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) is also considered a nano-cap.

In general, nano-cap companies have market capitalizations of less than $50 million. (4) Because nano-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. (9)

As of 1/8/2024, NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has a market cap of just around $1.2 million according to Finviz.com. (2)

Which is why things could get very interesting for NovaBay Pharmaceuticals, Inc. (AMEX: NBY).

NovaBay Pharmaceuticals Shines on QVC: A Game-Changer for Dermatology Brand (33)

Image Source (34)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) made waves in the skincare industry with its appearance on the renowned shopping network, QVC. Back in June 2023, the company unveiled an exciting collaboration with DERMAdoctor® to feature their KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin on QVC, offering consumers a special deal and a unique opportunity to experience these dermatologist-tested products.(33)

NovaBay Pharmaceuticals, Inc. was a company at the forefront of innovation in the dermatology and skincare sector. Their partnership with DERMAdoctor, a brand known for its commitment to skin health and simplicity in skincare routines, opened new doors for both companies. Dr. Audrey Kunin, NovaBay’s Chief Product Officer and a board-certified dermatologist, took center stage on QVC’s “Girls Night In with Courtney & Jane” on June 13, 2023. This appearance introduced their game-changing products to a wider audience, creating a buzz in the skincare world.(33)

The spotlight of this collaboration was the DERMAdoctor KP Duty Ultra Duo, which comprised the KP Duty Scrub and KP Duty Lotion, each in an 8-ounce size, offered at the special price of $56.50 during their QVC debut. These two products were designed as a two-step system to help address the issues of dry, rough, and bumpy skin. Dr. Kunin highlighted the primary benefits of the Ultra Duo, stating, “Our KP Duty Ultra Duo is specially formulated as a two-step system to help temporarily exfoliate, smooth, and hydrate dry, rough, and bumpy skin on the body, together with moisturizers to help hydrate for softer, more supple, and smoother-looking skin.” (33)

What set these products apart was their dermatologist-tested, non-irritating formula, making them suitable for year-round use. Dr. Kunin’s expertise and commitment to skincare played a pivotal role in ensuring the efficacy and safety of these products. As a recognized trailblazer in the skincare industry, she had dedicated herself to simplifying skincare routines while delivering measurable results for common skincare concerns. (33)

The KP Duty Body Scrub was powered by a 10% complex of Alpha Hydroxy Acids and Polyhydroxy Acids, providing both physical and chemical exfoliation to temporarily remove dead surface skin cells. Additionally, it contained a hydrating botanical blend of Evening Primrose, Black Currant Seed Oil, Borage Seed Oil, and White Tea Leaf Extract. (33)

Complementing the scrub, the KP Duty Lotion also featured a 10% complex of Alpha Hydroxy Acids and Polyhydroxy Acids. This combination worked to temporarily exfoliate the skin, improving skin texture and smoothness. The inclusion of ceramides, botanicals, and the humectant Urea helped to temporarily hydrate and moisturize the skin, leaving it looking and feeling revitalized.

QVC’s platform offered a unique opportunity for NovaBay Pharmaceuticals, Inc. and DERMAdoctor to showcase their innovative skincare solutions to a vast and diverse audience. It wasn’t just about selling products; it was about educating consumers on the importance of proper skincare and the benefits of using high-quality, dermatologist-tested products.

This appearance on QVC represented a significant milestone for NovaBay Pharmaceuticals, Inc. (AMEX: NBY). The exposure garnered from this partnership had the potential to catapult the brand into the mainstream, elevating its status in the skincare industry. Moreover, it provided consumers with the opportunity to access professional-grade skincare products at an affordable price point, backed by the expertise of Dr. Audrey Kunin and the reputation of DERMAdoctor. (33)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) Has the Only USDA-Certified Organic Lubricant Eye Drops on the Market. (10)

Image Source (10)

On March 14, 2023, NovaBay Pharmaceuticals, Inc. (AMEX: NBY) announced a partnership with Eyeganics to sell OTC Organic Tears (0.2% organic glycerin) on Avenova.com and through Avenova’s physician-dispensed channel. Organic Tears has no additives or artificial chemicals and is the only lubricant eye drop certified by the USDA as 100% organic and preservative-free. 

Organic Tears are formulated using only three ingredients – organic glycerin (oil from organic vegetables), salt, and water – and are extremely refreshing to dry eyes. A new technology allows for each bottle to dispense more than 250 drops of Organic Tears, providing a cost and convenience advantage over other preservative-free artificial tears found in single-use vials.

“Dry eye is a multifaceted and complex condition that’s becoming increasingly common. We’ve now added another high-quality, scientifically formulated product to Avenova.com that further reinforces our website as a one-stop designation for customers seeking relief from the symptoms of dry eye,” said Justin Hall, NovaBay CEO. (10)

“This product fills a need in our product assortment by offering a preservative-free dry eye drop. Our partnership with Eyeganics is the first of what we hope will be other highly effective ophthalmic products added to our distribution channels.”

“As a practicing eye doctor, I talk to a lot of patients about what eye drops they use,” said Eyeganics founder and CEO Dan Friederich, OD, FAAO. “I developed this product with all-natural ingredients to address the needs of patients affected by some chemicals that may be found in other artificial tears. I’m delighted to partner on this opportunity and to associate Organic Tears with the high-quality products available on Avenova.com.” (10)

Image Source (12)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) develops and sells scientifically created and clinically proven eye care and skincare products. NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eye care consumers through online distribution channels such as Amazon. (10)

Image Source (5)

DERMAdoctor® offers more than 30 OTC dermatologist-developed skin care products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. (10) 

NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products.

The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd. (10)

Breakthrough Eye Health Support Supplement Launched by NovaBay Pharmaceuticals, Inc. (AMEX: NBY)

Image Source (11)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has made a remarkable stride in the field of eye care with the launch of their new oral supplement, OTC Avenova Eye Health Support, which is designed to provide relief to dry eyes and promote overall eye health. The supplement, introduced on March 07, 2023, combines MaquiBright® – an antioxidant-rich extract of the maqui berry superfruit – with high-quality natural triglyceride omega-3 oils. This innovative product aims to address the increasing prevalence of dry eyes, a condition exacerbated by factors such as extended screen time, air pollution, and indoor heating and cooling. NovaBay Pharmaceuticals’ CEO, Justin Hall, highlighted that up to 49 million Americans suffer from dry eyes, and the global market for dry eye products is projected to reach nearly $9 billion by 2030. (11)

Avenova Eye Health Support comes in the form of 60 easy-to-swallow soft gel capsules, providing a 30-day supply. It is available for purchase on Amazon.com and Avenova.com, priced at $41.95. Additionally, it can be obtained through optometrist offices participating in NovaBay’s physician-dispensed channel.

The key ingredient in this oral supplement, MaquiBright® extract, has been clinically tested, showing promising results. In a four-week, randomized, double-blind, placebo-controlled study, participants experienced an 89% increase in tear production and reported a 57% improvement in dry eye discomfort when using Avenova Eye Health Support. These findings were published in the peer-reviewed Journal of Traditional and Complementary Medicine.

NovaBay Pharmaceuticals is committed to innovation in the eyecare sector and expanding its portfolio of evidence-backed, high-quality products. Avenova Eye Health Support represents the company’s latest effort to provide effective solutions for the multifaceted issue of dry eyes. (11)

This oral supplement complements Avenova’s existing range of scientifically developed eye care products, creating a comprehensive dry-eye treatment regimen. This range includes the renowned Avenova antimicrobial lid and lash spray for cleansing, lubricating eye drops for instant relief, warm eye compresses for soothing, dietary supplements of omega-3 oils, and the i-Check for monitoring physical eyelid health. All Avenova products are available directly to consumers through online distribution channels like Amazon and Avenova.com. (11)

In parallel to their product launch, NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has announced two innovative programs – the Avenova Loyalty Program and Avenova Affiliate Program – designed to benefit ophthalmologists and optometrists. These initiatives aim to support healthcare professionals in addressing chronic dry eye symptoms through the use of Avenova-branded products. (29)

NovaBay Pharmaceuticals, Inc. is well-regarded for its commitment to developing and commercializing high-quality products that enhance patients’ well-being. Avenova, their flagship product, has gained recognition as the No. 1 doctor-recommended lid and lash cleanser for managing the discomfort associated with chronic dry eye syndrome. The introduction of these programs highlights NovaBay’s dedication to fostering strong partnerships with eye care professionals and raising awareness of its comprehensive range of Avenova products, encompassing not only the renowned Avenova spray but also warm eye compresses, i-chek, lubricating drops, and oral supplements. (29)

Justin Hall, CEO of NovaBay Pharmaceuticals, expressed his enthusiasm for these initiatives, stating, “Avenova spray is the No. 1 doctor-recommended lid and lash cleanser, and we are delighted to offer these partnership opportunities to grow this important sales channel.” (29)

The Avenova Loyalty Program recognizes and rewards eyecare professionals who consistently recommend and prescribe Avenova products. It offers exclusive promotions and benefits to top Avenova eye care professionals, strengthening relationships with healthcare providers and encouraging continued recommendations to patients with chronic dry eye.

The Avenova Affiliate Program aims to expand the reach of Avenova products through a network of affiliated eye care professionals. This program benefits both professionals and patients by increasing awareness of the full suite of Avenova products available to alleviate dry eye symptoms.

NovaBay Pharmaceuticals, Inc. is actively engaging with eyecare professionals to enhance patient care and make a meaningful difference in the lives of those who suffer from dry eye symptoms. With millions of individuals affected by chronic dry eye worldwide, these initiatives are poised to play a significant role in improving ocular health. (29)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) continues to make strides in providing high-quality solutions for eye care. The launch of OTC Avenova Eye Health Support and the introduction of the Avenova Loyalty Program and Avenova Affiliate Program reflect the company’s commitment to innovation, product diversity, and strong partnerships with healthcare professionals. These initiatives hold great promise for enhancing patient care and addressing the multifaceted challenges of chronic dry eye. NovaBay’s dedication to improving ocular health remains evident in their ongoing efforts to offer comprehensive eye care solutions. (11)(29)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) Expands Commercial and Collaborative Strategies in $30 Billion Wound Care Market (13)

Image Source (14)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) is making significant strides in both the wound care and skincare markets. On January 17, 2023, PhaseOne Health, in collaboration with NovaBay Pharmaceuticals, Inc., announced the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser. This expansion involves collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States. PhaseOne Skin and Wound Care Cleanser is formulated with NovaBay’s patented, stable hypochlorous acid. (13)

The wound care market is substantial, with psoriasis alone affecting approximately 125 million people worldwide and nearly 8 million individuals in the United States. Recognizing this opportunity, NovaBay Pharmaceuticals, Inc. is excited to partner with PhaseOne Health to expand its sales in the coming year, as stated by Justin Hall, the CEO of NovaBay Pharmaceuticals.

Kris Perkins, Managing Director of PhaseOne Health, further explained that their goal is to build on their triple-digit percentage growth over the last few years by expanding their commercial programs in 2023. Their success in new clinical applications has positioned them well to pursue synergistic business and protocol development with other companies and providers, not only in wound care but in other surgical applications as well.

PhaseOne Skin and Wound Care Cleanser is composed of pure hypochlorous acid (HOCl), a part of the body’s natural immune system. HOCl is known for its safety and effectiveness in managing biofilm, bacteria, and fungi to promote the healing process. While PhaseOne is primarily used for pre- and post-plastic surgery procedures, the coming year will see an increased focus on the wound care market.

What sets PhaseOne apart in the wound care market is its utilization of NovaBay’s unique formulation of HOCl. NovaBay Pharmaceuticals, Inc. ensures the safest, purest, and most powerful HOCl wound cleanser on the market through its proprietary manufacturing process and amber glass bottle. This effectiveness has been independently documented in various studies, including the Comparative Antimicrobial Activity study published in the peer-reviewed journal Annals of Plastic Surgery. (13)

Jack Fisher, MD, Chief Medical Officer of PhaseOne Health, emphasized the significance of this study, highlighting the efficacy of HOCl in penetrating biofilm and killing bacteria and fungi. He also noted the trend for faster action when HOCl is stored in UV-resistant glass, such as PhaseOne’s packaging, compared to plastic. This research underscores the importance of purity and speed in wound care.

Looking ahead, PhaseOne Health plans to expand its efforts in partnering with organizations committed to providing more efficient, cost-effective healing solutions and therapies for wound and burn patients. They also plan to support independent studies exploring the utilization of PhaseOne in various specializations. (13)

In another development, NovaBay Pharmaceuticals, Inc. has fulfilled a significant order for its NeutroPhase Skin and Wound Cleanser, totaling $1 million, for China Pioneer Pharma Holdings, Limited. NovaBay’s partnership with China Pioneer, a prominent importer and marketer of branded pharmaceuticals and medical devices in China, demonstrates its growing presence in the international market. This order has been successfully fulfilled, with revenue expected to be recognized in the second quarter of 2023. (25)

NeutroPhase, developed by NovaBay Pharmaceuticals, Inc., is a highly effective and safe hypochlorous acid wound cleanser known for its superior purity, power, and gentleness on the skin and new tissue. It stands out for not containing toxic chemicals, making it a preferred choice among healthcare professionals. The product is manufactured in the United States through a proprietary process that ensures large batch quantities are produced. (25)

According to Justin Hall, the CEO of NovaBay Pharmaceuticals, NeutroPhase’s efficacy is unparalleled in the wound care market. It can kill bacteria that infect wounds, neutralize toxins that impede healing, and destroy healthy tissue. Additionally, NeutroPhase can safely penetrate biofilm, a major obstacle to wound healing. (25)

China Pioneer Pharma Holdings, Limited, led by Chairman Paul Li, is proud of its long-standing partnership with NovaBay and its commitment to offering high-quality products to healthcare customers in China. They aim to benefit patients across the country. (25)

The partnership between NovaBay Pharmaceuticals, Inc. and China Pioneer Pharma Holdings, Limited highlights the global demand for innovative wound care solutions. As NovaBay continues to expand its presence and deliver effective products like NeutroPhase to international markets, it reinforces its position as a leader in the field of advanced wound care. (25)

Do not wait on NovaBay Pharmaceuticals, Inc. (AMEX: NBY), pull it up now and it to your daily watch list.

Analyst Eyes Over 2,277% in Upside Potential with a $3.50 Target as This Low-Float BioPharma Comes Off its 52-Week Low… (27)(1)

See why now could be the best time to start your research on NovaBay Pharmaceuticals, Inc. (AMEX: NBY)

5 Reasons Why NovaBay Pharmaceuticals, Inc. (AMEX: NBY) Could Be Poised For Significant Upside Potential as we Move into 2024!

1. Positive Analyst Outlook: Director of Research and Senior Analyst for Ascendiant Capital Markets, LLC, Edward Woo, has recently conveyed optimistic views and offered favorable perspectives on NovaBay Pharmaceuticals, Inc. (AMEX: NBY) with a $3.50 target, , which suggests over 2,277% in potential upside from its 52-week low. (27)  

2. Strong Q3 Results: Recently, NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) unveiled its financial results for the third quarter of 2023, and the figures reveal an encouraging and promising narrative for the company. This announcement provides valuable insights into NovaBay’s performance and strategic direction, shedding light on their achievements and plans for the future.

3. QVC Collaboration: NovaBay’s collaboration with QVC represents a strategic move towards expanding its market reach. QVC is a widely recognized and trusted shopping network that reaches millions of viewers, providing a platform for NovaBay to showcase its dermatology products to a diverse and extensive audience. (33)

4. Robust Product Portfolio: NovaBay Pharmaceuticals, Inc. (AMEX: NBY) boasts a robust product portfolio, including its Avenova-branded eye care products, DERMAdoctor skin care products, and PhaseOne wound care products. This diverse range of offerings positions the company well within the healthcare industry and presents multiple avenues for growth. (19)

5. Promising Future: NovaBay Pharmaceuticals, Inc. (AMEX: NBY)’s recent achievements, including the shipment of a significant order for NeutroPhase Skin and Wound Cleanser, highlight their potential for future success. The company’s ongoing initiatives and strategic partnerships indicate a commitment to capitalizing on market opportunities and delivering long-term value. (20)

SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & NEWS.

Getting the Right News Before Everyone Else Does, is FREE…

Terms | Privacy Policy Message and data rates may apply. Reply STOP keyword to be opted out of the program. Reply Help for Help. We will never sell or share to third parties. For informational purposes only.

Important: For faster alerts, join our Telegram & WhatsApp groups! Don’t miss a beat in the market.

Source 1: https://www.barchart.com/stocks/quotes/NBY/price-history/historical
Source 2: https://finviz.com/quote.ashx?t=NBY&p=d
Source 3: https://www.sofi.com/learn/content/understanding-low-float-stocks/
Source 4: https://www.investopedia.com/terms/n/nanocap.asp
Source 5: https://s3.amazonaws.com/b2icontent.irpass.cc/2807/189210.pdf
Source 6: https://www.verifiedmarketresearch.com/product/eye-care-products-market/
Source 7: https://schrts.co/CSUqrZCC
Source 8: https://public.ortex.com/wp-content/uploads/2022/04/1978109978-huge-scaled.jpg
Source 9: https://www.benzinga.com/money/best-nano-cap-stocks
Source 10: https://finance.yahoo.com/news/eyeganics-organic-tears-only-usda-105000743.html
Source 11: https://finance.yahoo.com/news/novabay-pharmaceuticals-launches-avenova-eye-115000785.html
Source 12: https://pbs.twimg.com/media/FrNDOEEWYAAKqnv?format=jpg&name=900×900
Source 13: https://finance.yahoo.com/news/phaseone-health-novabay-pharmaceuticals-expand-115000665.html
Source 14: https://finance.yahoo.com/news/wound-care-market-size-estimated-143500120.html
Source 15: https://cdn.aelieve.com/5bdb71c4-nby-2023.04.02-q4-2022-earnings.pdf
Source 16: https://www.precedenceresearch.com/ophthalmic-drugs-market
Source 17: https://www.precedenceresearch.com/psoriasis-treatment-market
Source 18: https://www.precedenceresearch.com/cosmetics-market
Source 19: https://s3.amazonaws.com/b2icontent.irpass.cc/2807/190104.pdf
Source 20: https://finance.yahoo.com/news/novabay-pharmaceuticals-reports-first-quarter-200500375.html
Source 21 :https://schrts.co/QkkDUJtd
Source 22: https://ascendiant.com/team/edward-m-woo-cfa/
Source 23: https://www.businesswire.com/news/home/20230421005008/en/NovaBay-Pharmaceuticals-Launches-DERMAdoctor%E2%80%99s-New-Comfort-Joy-Psoriasis-Therapeutic-Moisturizing-Cream-on-the-QVC%C2%AE-Network
Source 24: https://scontent-lga3-2.xx.fbcdn.net/v/t39.30808-6/342377042_243681768183219_2409397133869954872_n.jpg?_nc_cat=107&ccb=1-7&_nc_sid=730e14&_nc_ohc=aDL38ldy1A8AX-eKGBN&_nc_ht=scontent-lga3-2.xx&oh=00_AfBkMLQJQPwFrw8V-FKDPzKo5HaYbei3nrU8UrL4H3PiyQ&oe=647B57E6
Source 25: https://finance.yahoo.com/news/novabay-pharmaceuticals-fulfills-1-million-105000124.html
Source 26: https://novabay.com/products/neutrophase/
Source 27: https://cdn.aelieve.com/522b2bce-nby-2023.12.07-q3-2023-earnings.pdf
Source 28: https://www.marketwatch.com/investing/stock/nby?mod=search_symbol
Source 29: https://finance.yahoo.com/news/novabay-pharmaceuticals-expands-physician-dispensed-120000896.html
Source 30: https://finance.yahoo.com/news/novabay-pharmaceuticals-reports-third-quarter-210500105.html
Source 31: https://www.urenco.com/cdn/imgsizer/cdn/uploads/content-images/1000–65-Financial-results-880×380.jpg
Source 32: https://www.otcmarkets.com/stock/NBY/overview
Source 33: https://finance.yahoo.com/news/novabay-pharmaceuticals-announces-dermadoctor-kp-105000435.html
Source 34: https://qvc.scene7.com/is/image/QVC/a/63/a460763.001?$aempdzoom$

 

SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & NEWS.

Getting the Right News Before Everyone Else Does, is FREE…

Terms | Privacy Policy Message and data rates may apply. Reply STOP keyword to be opted out of the program. Reply Help for Help. We will never sell or share to third parties. For informational purposes only.

Important: For faster alerts, join our Telegram & WhatsApp groups! Don’t miss a beat in the market.